| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 17.45% | JP Morgan | $8 → $7 | Maintains | Underweight |
| 08/14/2023 | -16.11% | Morgan Stanley | $7 → $5 | Maintains | Underweight |
| 08/14/2023 | 84.56% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 07/25/2023 | 269.13% | Canaccord Genuity | $21 → $22 | Maintains | Buy |
| 06/07/2023 | 252.35% | Canaccord Genuity | → $21 | Reiterates | Buy → Buy |
| 05/15/2023 | 101.34% | B of A Securities | $6 → $12 | Maintains | Neutral |
| 05/10/2023 | 17.45% | Morgan Stanley | $4 → $7 | Maintains | Underweight |
| 05/10/2023 | 118.12% | Wedbush | $5 → $13 | Upgrades | Neutral → Outperform |
| 05/09/2023 | 252.35% | Canaccord Genuity | $18 → $21 | Maintains | Buy |
| 04/04/2023 | 84.56% | HC Wainwright & Co. | $19 → $11 | Maintains | Buy |
| 04/03/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/01/2023 | 0.67% | B of A Securities | → $6 | Maintains | Neutral |
| 03/31/2023 | 202.01% | Canaccord Genuity | $20 → $18 | Maintains | Buy |
| 01/30/2023 | 118.12% | BMO Capital | $12 → $13 | Maintains | Outperform |
| 01/27/2023 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
| 01/05/2023 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 12/15/2022 | 0.67% | B of A Securities | $5 → $6 | Maintains | Neutral |
| 12/02/2022 | -16.11% | B of A Securities | $23 → $5 | Downgrades | Buy → Neutral |
| 11/01/2022 | 101.34% | BMO Capital | $29 → $12 | Maintains | Outperform |
| 10/31/2022 | 353.02% | Canaccord Genuity | $35 → $27 | Maintains | Buy |
| 10/31/2022 | 34.23% | Morgan Stanley | $17 → $8 | Maintains | Equal-Weight |
| 10/31/2022 | 0.67% | Wedbush | → $6 | Downgrades | Outperform → Neutral |
| 10/31/2022 | 218.79% | HC Wainwright & Co. | $63 → $19 | Maintains | Buy |
| 10/31/2022 | 17.45% | JP Morgan | $16 → $7 | Downgrades | Neutral → Underweight |
| 09/09/2022 | 185.23% | Morgan Stanley | $15 → $17 | Maintains | Equal-Weight |
| 06/24/2022 | 353.02% | BMO Capital | → $27 | Initiates Coverage On | → Outperform |
| 02/28/2022 | 957.05% | HC Wainwright & Co. | $68 → $63 | Maintains | Buy |
| 01/03/2022 | 353.02% | JP Morgan | $30 → $27 | Maintains | Neutral |
| 11/16/2021 | 403.36% | JP Morgan | $57 → $30 | Downgrades | Overweight → Neutral |
| 06/28/2021 | 1040.94% | HC Wainwright & Co. | $70 → $68 | Maintains | Buy |
| 05/07/2021 | 839.6% | B of A Securities | $56 → $56 | Upgrades | Neutral → Buy |
| 03/22/2021 | 772.48% | JP Morgan | → $52 | Assumes | → Overweight |
| 03/01/2021 | 1074.5% | HC Wainwright & Co. | $65 → $70 | Maintains | Buy |
| 01/15/2021 | 839.6% | B of A Securities | → $56 | Downgrades | Buy → Neutral |
| 11/12/2020 | 655.03% | Morgan Stanley | $42 → $45 | Maintains | Equal-Weight |
| 11/09/2020 | 990.6% | HC Wainwright & Co. | $52 → $65 | Maintains | Buy |
| 10/07/2020 | 671.81% | B of A Securities | $48 → $46 | Upgrades | Neutral → Buy |
| 07/15/2020 | 604.7% | Morgan Stanley | $39 → $42 | Maintains | Equal-Weight |
| 05/11/2020 | 772.48% | HC Wainwright & Co. | $41 → $52 | Reiterates | → Buy |
| 05/05/2020 | 638.26% | Barclays | → $44 | Initiates Coverage On | → Overweight |
| 05/01/2020 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 01/28/2020 | 587.92% | HC Wainwright & Co. | $40 → $41 | Reiterates | → Buy |
| 12/24/2019 | 554.36% | JP Morgan | → $39 | Initiates Coverage On | → Overweight |
| 11/20/2019 | 571.14% | Guggenheim | → $40 | Initiates Coverage On | → Buy |
| 10/29/2019 | 621.48% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 10/28/2019 | 571.14% | Canaccord Genuity | $35 → $40 | Maintains | Buy |
| 09/04/2019 | 537.58% | Wedbush | → $38 | Initiates Coverage On | → Outperform |
| 04/01/2019 | 504.03% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
What is the target price for Y-mAbs Therapeutics (YMAB)?
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by JP Morgan on August 22, 2023. The analyst firm set a price target for $7.00 expecting YMAB to rise to within 12 months (a possible 17.45% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Y-mAbs Therapeutics (YMAB)?
The latest analyst rating for Y-mAbs Therapeutics (NASDAQ: YMAB) was provided by JP Morgan, and Y-mAbs Therapeutics maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Y-mAbs Therapeutics (YMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
Is the Analyst Rating Y-mAbs Therapeutics (YMAB) correct?
While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a maintained with a price target of $8.00 to $7.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $5.96, which is out of the analyst's predicted range.